Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial
Identifieur interne : 009742 ( Main/Merge ); précédent : 009741; suivant : 009743Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial
Auteurs : Philippe Bernard ; Olivier Chosidow ; Loïc VaillantSource :
- BMJ : British Medical Journal [ 0959-8138 ] ; 2002.
Abstract
To assess the efficacy and safety of oral pristinamycin versus intravenous then oral penicillin to treat erysipelas in patients in hospital.
Multicentre, parallel group, open labelled, randomised non-inferiority trial.
22 French hospitals.
289 adults admitted to hospital with erysipelas.
At follow up (day 25-45) the cure rate (primary efficacy end point) for the per protocol populations was 81% (83/102) for pristinamycin and 67% (68/102) for penicillin. The planned interim analysis (global one sided type I error 5%) showed that the one sided 97.06% confidence interval of the observed difference (pristinamycin−penicillin) between cure rates (3.3% to ∞) exceeded the −10% non-inferiority threshold. For the intention to treat populations the cure rate at follow up was 65% (90/138) for pristinamycin and 53% (79/150) for penicillin, with the one sided 97.06% confidence interval of the observed difference between cure rates (1.7% to ∞) exceeding the −10% non-inferiority threshold. That the lower limit of the confidence interval exceeded the –10% threshold and was also >0 supports the hypothesis that pristinamycin is significantly superior at the 5% level. More adverse events related to treatment, as assessed by the investigators, were reported in the pristinamycin group than in the penicillin group. Most adverse events involved the gastrointestinal tract (nausea, vomiting, and diarrhoea) but were minor and usually did not require discontinuation of treatment.
Pristinamycin could be an alternative to the standard intravenous then oral penicillin regimen used to treat erysipelas in adults in hospital, with the advantages of oral first line therapy.
The reference treatment for erysipelas is intravenous penicillin, which requires admission to hospital Few studies have evaluated the efficacy of oral treatment for erysipelas Oral pristinamycin is at least as effective as intravenous then oral penicillin to treat erysipelas in adult inpatients, with the advantage of oral first line treatment
Url:
PubMed: 12386036
PubMed Central: 129632
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000A97
- to stream Pmc, to step Curation: 000A96
- to stream Pmc, to step Checkpoint: 003F46
- to stream Ncbi, to step Merge: 000B33
- to stream Ncbi, to step Curation: 000B33
- to stream Ncbi, to step Checkpoint: 000B33
Links to Exploration step
PMC:129632Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial</title><author><name sortKey="Bernard, Philippe" sort="Bernard, Philippe" uniqKey="Bernard P" first="Philippe" last="Bernard">Philippe Bernard</name><affiliation><nlm:aff id="N0x9519048.0x98ad878"></nlm:aff></affiliation></author><author><name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name><affiliation><nlm:aff id="N0x9519048.0x98ad878"></nlm:aff></affiliation></author><author><name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loïc" last="Vaillant">Loïc Vaillant</name><affiliation><nlm:aff id="N0x9519048.0x98ad878"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">12386036</idno><idno type="pmc">129632</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC129632</idno><idno type="RBID">PMC:129632</idno><date when="2002">2002</date><idno type="wicri:Area/Pmc/Corpus">000A97</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A97</idno><idno type="wicri:Area/Pmc/Curation">000A96</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000A96</idno><idno type="wicri:Area/Pmc/Checkpoint">003F46</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003F46</idno><idno type="wicri:Area/Ncbi/Merge">000B33</idno><idno type="wicri:Area/Ncbi/Curation">000B33</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B33</idno><idno type="wicri:doubleKey">0959-8138:2002:Bernard P:oral:pristinamycin:versus</idno><idno type="wicri:Area/Main/Merge">009742</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial</title><author><name sortKey="Bernard, Philippe" sort="Bernard, Philippe" uniqKey="Bernard P" first="Philippe" last="Bernard">Philippe Bernard</name><affiliation><nlm:aff id="N0x9519048.0x98ad878"></nlm:aff></affiliation></author><author><name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name><affiliation><nlm:aff id="N0x9519048.0x98ad878"></nlm:aff></affiliation></author><author><name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loïc" last="Vaillant">Loïc Vaillant</name><affiliation><nlm:aff id="N0x9519048.0x98ad878"></nlm:aff></affiliation></author></analytic><series><title level="j">BMJ : British Medical Journal</title><idno type="ISSN">0959-8138</idno><idno type="eISSN">1468-5833</idno><imprint><date when="2002">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective</title><p>To assess the efficacy and safety of oral pristinamycin versus intravenous then oral penicillin to treat erysipelas in patients in hospital.</p></sec><sec><title>Design</title><p>Multicentre, parallel group, open labelled, randomised non-inferiority trial.</p></sec><sec><title>Setting</title><p>22 French hospitals.</p></sec><sec><title>Participants</title><p>289 adults admitted to hospital with erysipelas.</p></sec><sec><title>Results</title><p>At follow up (day 25-45) the cure rate (primary efficacy end point) for the per protocol populations was 81% (83/102) for pristinamycin and 67% (68/102) for penicillin. The planned interim analysis (global one sided type I error 5%) showed that the one sided 97.06% confidence interval of the observed difference (pristinamycin−penicillin) between cure rates (3.3% to ∞) exceeded the −10% non-inferiority threshold. For the intention to treat populations the cure rate at follow up was 65% (90/138) for pristinamycin and 53% (79/150) for penicillin, with the one sided 97.06% confidence interval of the observed difference between cure rates (1.7% to ∞) exceeding the −10% non-inferiority threshold. That the lower limit of the confidence interval exceeded the –10% threshold and was also >0 supports the hypothesis that pristinamycin is significantly superior at the 5% level. More adverse events related to treatment, as assessed by the investigators, were reported in the pristinamycin group than in the penicillin group. Most adverse events involved the gastrointestinal tract (nausea, vomiting, and diarrhoea) but were minor and usually did not require discontinuation of treatment.</p></sec><sec><title>Conclusion</title><p>Pristinamycin could be an alternative to the standard intravenous then oral penicillin regimen used to treat erysipelas in adults in hospital, with the advantages of oral first line therapy.</p><p> <boxed-text><sec><title>What is already known on this topic</title><p>The reference treatment for erysipelas is intravenous penicillin, which requires admission to hospital</p><p>Few studies have evaluated the efficacy of oral treatment for erysipelas</p></sec><sec><title>What this study adds</title><p>Oral pristinamycin is at least as effective as intravenous then oral penicillin to treat erysipelas in adult inpatients, with the advantage of oral first line treatment </p></sec></boxed-text></p></sec></div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009742 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 009742 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Merge
|type= RBID
|clé= PMC:129632
|texte= Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:12386036" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |